Larry Gold PhD

Lake N. Paul, PhD. is in San Diego at the Biotechnology Innovation Organization #BIO2024 conference meeting with colleagues & future clients. Connect with him in person to learn about how, as a Collaborative Research Organization, we are best positioned to support your analytical program. #aav #genetherapy #rarediseases #biophysics #STEM #STEMPhilly #biochemistry #celltherapy #bioanalysisllc #PhillyBusiness #phillyscience

9

🚀 Exciting News for Biocom California Members! 🚀 Your fellow member, Transition Services, Inc. (TSI), is hosting a game-changing, hour-long webinar on July 16th, 2024, at 11:00 AM PST that you will not want to miss! Discover a little-known separation benefits structure that can drastically cut your company's costs while providing an innovative alternative to traditional severance. 💡 𝐖𝐡𝐲 𝐀𝐭𝐭𝐞𝐧𝐝? 𝟏. 𝐈𝐧-𝐝𝐞𝐩𝐭𝐡 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠: Learn about SUB Plans, an IRS-sanctioned and tax-advantaged alternative to severance. 𝟐. 𝐋𝐞𝐠𝐚𝐥 𝐚𝐧𝐝 𝐓𝐚𝐱 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: Understand the benefits associated with SUB Plans. 𝟑. 𝐈𝐦𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬: Discover how to implement this flexible and cost-effective severance alternative. 𝟒. 𝐍𝐞𝐭𝐰𝐨𝐫𝐤𝐢𝐧𝐠 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬: Expand your professional network. Click the link below for more details and to secure your spot for this must-attend virtual event. Do not miss out on the opportunity to revolutionize your approach to employee separations! #employeeseparations #severancealternative #hrbenefits #supplementalunemploymentbenefits #costsavings #strategicplanning

2

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

Today is the last day of Antibody Engineering & Therapeutics in San Diego! Check out our poster, “Robust and Streamlined Approach for High-Throughput Sequencing of OmniRat Antibody Repertoires.” See our team in booth 300 to continue the conversation! #AntibodyEng

48

1 Comment

CytoAgents is an innovative, clinical-stage biotech company focused on bringing to market novel treatments for Cytokine Release Syndrome (CRS), an overreaction of the immune system. CytoAgents' solution targets cytokines specifically active in CRS, allowing treatment without disrupting normal immune system mechanisms. Learn more about CytoAgents and CRS here: https://cytoagents.com/ #cytoinereleasesyndrome #crs #cytokines Teresa Whalen, RPh

4

There are just 2 days left to submit your Abstracts for CYTO 2025! Don't miss your chance to educate and inspire others as you share your research in biological, life, and physical sciences. Learn more: https://lnkd.in/gyvkb6dw #CYTO2025 #CytometryResearch #CYTOeducation

7

🔬 A crucial discussion unfolded at #AAPSPharmSci360, as industry leaders tackled the FDA's transformative laboratory-developed test (LDT) proposed rule and its implications for biomarker testing at last month's conference in Salt Lake City.   The high-impact session, moderated by our Chief Scientific Officer, Dr. Lauren Stevenson, brought together expert perspectives from Stephen Piccoli (Sun Pharma), Patrice Hugo (IQVIA Laboratories), and Mark Ma (Rallybio).   The session revealed critical insights into the FDA's April 2024 LDT Final Rule, fundamentally reshaping how diagnostic and exploratory biomarker tests are regulated. Under this new framework, LDTs will transition from their current enforcement discretion policy to being regulated as medical devices.   The implications are significant: industry data suggests 200-400 clinical studies could face delays over the next three years, potentially affecting 30,000-45,000 patients. We're proud to see Immunologix Laboratories contributing to these vital industry discussions.   Read the full article by Bioanalysis Zone here: https://lnkd.in/eTvyRRgY   As a specialized bioanalytical CRO, we understand firsthand how these evolving regulations will reshape pharmaceutical development. Our expertise in this space allows us to offer strategic guidance to sponsors through:   💠 Sophisticated biomarker strategies coupled with depth of regulatory expertise 💠 Custom biomarker assay development and validation 💠 Method transfer and optimization for context of use 💠 PK/PD analysis This regulatory evolution presents both challenges and opportunities for our industry. As we look ahead, our scientific team remains committed to delivering innovative, compliant solutions that advance drug development programs and ultimately benefit patients.   Thank you to AAPS for facilitating these critical conversations that help shape the future of our industry!   #Bioanalysis #DrugDevelopment #Biomarkers #CRO #PharmaceuticalScience #RegulatoryScience #ImmunologixLabs

10

Are you attending the Sept. 25th San Francisco #AdvancedTherapiesXchange? Drawing on his 30+ years of experience leading immune cell operations, Kevin King, Senior Director of #CellandGeneTherapy Strategy and Growth at BioIVT, will be leading the 11:25am session “From Donor to Development: Minimizing Risks in the Cell Starting Materials Supply Chain” discussing strategies to de-risk the utilization of cellular starting and raw materials in the manufacture of #AdvancedTherapies: https://hubs.ly/Q02Qbz6B0 In the absence of industry-wide standardization of human cells, tissues, and cellular and tissue-based products (HCT/Ps), production and manufacturing processes are not equivalent among suppliers. This can create significant efficiency, quality and regulatory obstacles as therapeutic platforms transition from preclinical to clinical application. Kevin will also be joined by Lisa Kretzschmar, Senior Scientific Advisor for CGT at BioIVT, and Adam Ross, Technical Sales Specialist for CGT at BioIVT, for 1:1 meeting requests to discuss: - Why you need a partner that can take you from RUO to GMP - The value of having a geographically expansive, secure supply chain - The importance of donor diversity and its impact on your success - How BioIVT can support your CGT development, from discovery to clinical development Make sure to connect with our expert team if you’d like to schedule a meeting! Learn more about our CGT solutions: https://hubs.ly/Q02QbVwK0 #CellTherapy #GeneTherapy #ATMPs #hubXchange

14

🌟 Friday Read: Accelerating Drug Development with Spatial Biology 👉https://bit.ly/4aro6Lo Presage Biosciences, Inc.'s CIVO® platform, combined with GeoMx and CosMx technologies, effectively tracks anti-neoplastic and immune-modulating activity in the intact tumor microenvironment. This innovative approach is speeding up drug development and paving the way for more successful clinical trials.🔬 #SpatialBiology #DrugDevelopment #FridayRead This post may include information regarding CosMx™ SMI products for RNA detection, which products are not available in the Federal Republic of Germany, as further described here - https://lnkd.in/gUXh88Pr.

54

2 Comments

Are you attending #BIO2024? Our CBO Paul Wallace will be in San Diego June 3-6 and available to speak about how our unique technologies can enhance your biotherapeutics programs.    At Constructive Bio we recode entire genomes and engineer protein translation to enable the design of protein and peptide therapeutics that have unprecedented functionalities - creating the biomolecules of the future.     Together we can:   ✅ Develop the next-generation ADCs: optimize peptide and antibody drug conjugates (ADCs) by fine-tuning drug-antibody ratio (DAR) and payload location, incorporating dual payloads and improving the therapeutic index, stability and PK. (E. coli and CHO expression). ✅ Generate novel and stable incretin based therapies (GLP-1 RA and GIP etc) – and simplify their manufacture, and reduce COGs, by production in E. coli. ✅ Precisely locate multiple conjugation handles / click chemistries into therapeutics / modular proteins. ✅ Utilize a vast chemical space, beyond the 20 standard amino acids, significantly to improve the pharmaceutical properties and functionality of biological therapeutics.   Click here to set up a meeting https://lnkd.in/eAJSe8Zg or get in touch via email paul.wallace@constructivebio.com.

19

Parse Biosciences Partners with OMAPiX to Expand Access to Single Cell Sequencing https://lnkd.in/g-JD-ubt SEATTLE–(BUSINESS WIRE)–Parse Biosciences Partners with OMAPiX to Expand Access to Single Cell Sequencing Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

1

Please join Abiosciences on Sept 19th at 10x Genomics User Group meeting at Grand Hyatt - SFO (9:30 AM - 3:00 PM PT). Topics include: 1. Chromium GEM-X Single Cell Assays 2. Visium HD 3. Xenium Multimodal Segmentation, 5K, and In-line Protein 4. Data analysis Stop by our table to speak to our experts to discuss scRNA, spatial transcriptomics or data-analysis.

8

Join us at #ASGCT24, where we will showcase our neurology-focused pre-clinical pipeline, including data supporting innovations in zinc finger epigenetic regulation, advances in AAV capsid engineering, and discovery of our next-generation integrase technology.   Details here on our 20 abstracts that will be presented, https://bit.ly/3wf1Aai #genomemedicine #neurology #epigenetics #zincfinger

107

1 Comment

The top regional #healthcare and #biotech news for January 10th via the Big4Bio newsletters: San Diego: Timberlyne Therapeutics Launches With $180M; Shoreline Biosciences, Inc. Cuts Staff; Belharra Therapeutics Hires CSO https://lnkd.in/gP4pb3wY SF Bay: Exec Hires; Ouro Medicines, Kardigan Launch; Layoffs at IGM Biosciences, Inc.; Biotech Ecosystem Venture Fund https://lnkd.in/gGbr4gvn Seattle: Transcarent, Accolade, Inc. $621M Deal; Slaoui & Phelan Join Achieve Life Sciences Board; AGC Biologics, Pandorum Technologies Collab https://lnkd.in/gAhtyWxk Los Angeles: Biocom California's New Directors; TAE Life Sciences & Kyoto University Breakthrough BNCT Results; UC Irvine's Bioluminescent RNA https://lnkd.in/gHWSiS92 Boston: Exec Changes; City Therapeutics, etherna, HARBOUR BIOMED Strike Deals; Restructuring at Repare Therapeutics, Intellia Therapeutics, Inc. https://lnkd.in/g_M8nQBp Philadelphia: Kardigan Launches; RhyGaze AG Raises $86M; How Fungi Make a Key Medicinal Molecule https://lnkd.in/g-ydsewW Capital Region: VERALOX Therapeutics to Acquire Nudge; Danaher Corporation, Innovaccer Partnership; Hot Investor Mandates; More on Vanda Pharmaceuticals NYC: Kardigan Launches; Pacira BioSciences, Inc.'s Five-year Plan; Pfizer Prospect Beats Incumbent; More on Johnson & Johnson https://lnkd.in/gP-cTPRZ

5